Professor David Walker – Research into brain cancer identifies new target for treatment.

Dr David Walker has co-authored a research paper detailing the discovery of a protein, EphA3, that is found in about half of all glioblastoma multiforme tumours. It is believed the protein plays a role in maintaining cells which are in a tumourgenic state.

They have found that binding the antibody, known as IIIA4 and discovered by Andrew Boyd from QIMR more than 20 years ago, to a radioactive isotope has shown great promise in animal trials. An antibody treatment is already being trialled in the US in leukaemia patients.

The treatment is a few years away at this stage, as more trials need to be conducted in animals and then the funding will need to be raised.

The paper was published in the journal “Cancer Cell”.


Join our newsletter to keep informed on industry developments ...

Part of the Fortus Health Group

Newro Foundation Brizbrain and Spine